A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

such as adalimumab (Humira), golimumab (Simponi), and infliximab (Remicade) A medication called Janus kinase (JAK) inhibitors may also help reduce inflammation in certain types of arthritis.

in 2012 and J&J’s Simponi (golimumab) in 2013. In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors ...

In patients with inadequate remission or low disease activity, advanced therapies are indicated, including targeted synthetic DMARDs, such as biologic agents (tumor necrosis factor-alpha [TNFα] ...

Biologic DMARDs included were tumour necrosis factor inhibitors (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab), the T cell costimulation inhibitor abatacept, the anti-B ...

Multifocal cutaneous leishmaniasis in a patient treated with golimumab for psoriatic arthritis Veronica Forte 1, Anna Silvia Biamonte 2, Massimo Menichini 3, Fabrizio Liberati 1, Luca Ventura 1 ...

On May 21, 2025, Sandoz announced the commercial launch in Europe of its PYZCHIVA® (ustekinumab) autoinjector, “the first ustekinumab biosimilar in ...